| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capecitabine is an oral chemotherapy medication used primarily in the treatment of various cancers. Capecitabine is an antimetabolite chemotherapeutic agent. It's classified as a prodrug, meaning it is metabolized in the body to its active form, 5-fluorouracil (5-FU). Once ingested, capecitabine is absorbed and converted through a series of enzymatic reactions into 5-FU. 5-FU then interferes with DNA synthesis and RNA processing by inhibiting enzymes like thymidylate synthase. This disruption of nucleotide production hinders rapid cell division, making it effective against cancer cells that multiply quickly. One of the advantages of capecitabine is that it is taken by mouth in tablet form, as opposed to intravenous administration, which can be more convenient for patients Capecitabine — Capecitabine is an orally administered fluoropyrimidine carbamate prodrug that is converted through sequential enzymatic metabolism to 5-fluorouracil, with the final activation step mediated by thymidine phosphorylase, which is often relatively enriched in tumor tissue. It is formally classified as an antimetabolite cytotoxic chemotherapy and a 5-FU prodrug. Standard abbreviations include CAP and Cape; Clinically, capecitabine is a standard-of-care systemic agent rather than an experimental adjunct, with established regulatory use in colorectal, breast, gastric/GEJ, rectal chemoradiation, and pancreatic settings depending on regimen and jurisdiction. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral absorption is rapid, with median Tmax about 1.5 hours for capecitabine and about 2 hours for fluorouracil. Food lowers capecitabine and 5-FU exposure and delays Tmax, which is why labeling directs dosing within 30 minutes after a meal. Plasma protein binding is under 60%, terminal half-lives are short at about 0.75 hour for capecitabine and 5-FU, and urinary excretion is dominant. Renal impairment substantially raises exposure to metabolites, especially FBAL, making renal function clinically important for dosing and tolerability. In-vitro vs systemic exposure relevance: This is a prodrug whose relevance is pathway- and metabolism-dependent rather than parent-drug concentration alone. Many in-vitro studies using high capecitabine concentrations, enzyme-poor systems, or direct comparison with 5-FU can be misleading, because clinical activity depends on host and tumor enzymatic conversion and the downstream intracellular fluoropyrimidine metabolites rather than sustained high circulating parent-drug levels. Clinical evidence status: High-level clinical evidence and full deployment. Capecitabine has long-standing phase III and regulatory support as an approved fluoropyrimidine backbone or substitute for infusional 5-FU in several solid tumors, and it is routinely used both as monotherapy and in combination regimens, including chemoradiation contexts. Current safety regulation has become more restrictive because of DPD deficiency risk, with recent FDA and Canadian labeling/guidance emphasizing pre-treatment DPYD evaluation and avoidance in complete DPD deficiency. Mechanistic profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure. In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment. The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression. High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers. Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence. As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival. - vimentin up-regulation is often used as a marker of EMT in cancer |
| 7702- | IP6, | Ins, | capec, | Inositol Hexakisphosphate and Inositol Enhance the Inhibition of Colorectal Cancer Growth and Liver Metastasis by Capecitabine in a Mouse Model |
| - | in-vivo, | CRC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:328 Target#:336 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid